Related references
Note: Only part of the references are listed.Regulation of PD-L1 expression in the tumor microenvironment
Ming Yi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial
Kai-Lin Yang et al.
RADIATION ONCOLOGY (2021)
Risk factors for osteoradionecrosis of the jaw in patients with head and neck squamous cell carcinoma
Hikaru Kubota et al.
RADIATION ONCOLOGY (2021)
Monotherapy and Combination Therapy Using Anti-Angiogenic Nanoagents to Fight Cancer
Pingping Liang et al.
ADVANCED MATERIALS (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Kathleen N. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents
Anna Wrona et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment
Linbang Wang et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
Chung-Han Lee et al.
LANCET ONCOLOGY (2021)
HIF2-Induced Long Noncoding RNA RAB11B-AS1 Promotes Hypoxia-Mediated Angiogenesis and Breast Cancer Metastasis
Yanling Niu et al.
CANCER RESEARCH (2020)
Ramucirumab: A Review in Hepatocellular Carcinoma
Yahiya Y. Syed
DRUGS (2020)
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
Raluca Ioana Teleanu et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Yolla Haibe et al.
FRONTIERS IN ONCOLOGY (2020)
Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models
Qiaohong Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naive older or frail patients with metastatic colorectal cancer (OGSG 0802)
Takashi Ohta et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations
Martin Reck et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2020)
Safety and Effectiveness of Aflibercept plus Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study
Ian Chau et al.
CANCERS (2020)
Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma
Pedro Miguel Lacal et al.
PHARMACOLOGICAL RESEARCH (2020)
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
Vivek Subbiah et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)
Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
Yung-Jue Bang et al.
EUROPEAN JOURNAL OF CANCER (2020)
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Andrea B. Apolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer A Secondary Analysis of the AVANT Trial
Benoist Chibaudel et al.
JAMA NETWORK OPEN (2020)
Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results
Ramon Salazar et al.
BMC CANCER (2020)
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
Elisabeth Perez-Ruiz et al.
DRUG RESISTANCE UPDATES (2020)
Heparanase and the hallmarks of cancer
Krishnath M. Jayatilleke et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma
Shuang Qin et al.
JOURNAL OF CANCER (2020)
FGF/FGFR signaling pathway involved resistance in various cancer types
Yangyang Zhou et al.
JOURNAL OF CANCER (2020)
VEGF/Neuropilin Signaling in Cancer Stem Cells
Arthur M. Mercurio
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Shuang Qin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
Nieves Martinez Changa et al.
LANCET ONCOLOGY (2019)
First-line avelumab plus axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
Masatoshi Kudo et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
Yusuke Tomita et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients
Emma Boydell et al.
CANCERS (2019)
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
Breelyn A. Wilky et al.
LANCET ONCOLOGY (2019)
IL-1 Family Cytokine Regulation of Vascular Permeability and Angiogenesis
Erin Fahey et al.
FRONTIERS IN IMMUNOLOGY (2019)
Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer
Stephanie O. Dudzinski et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine
Caterina Lapenta et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin et al.
MOLECULAR CANCER (2019)
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer A Phase 2 Clinical Trial
Joyce F. Liu et al.
JAMA ONCOLOGY (2019)
Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease
Florence T. H. Wu et al.
BRITISH JOURNAL OF CANCER (2019)
Contribution of Angiogenesis to Inflammation and Cancer
Dolores Aguilar-Cazares et al.
FRONTIERS IN ONCOLOGY (2019)
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
Divya Sakamuri et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary
Simron Singh et al.
NEUROENDOCRINOLOGY (2018)
Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model
Paola Bocca et al.
ONCOIMMUNOLOGY (2018)
Mechanisms of Resistance to PD-1 and PD-L1 Blockade
Theodore S. Nowicki et al.
CANCER JOURNAL (2018)
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
Lydia Meder et al.
CANCER RESEARCH (2018)
Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models
Dipongkor Saha et al.
CLINICAL CANCER RESEARCH (2018)
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins et al.
LANCET ONCOLOGY (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)
Hendrik-Tobias Arkenau et al.
ONCOLOGIST (2018)
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
Ahmed M. E. Abdalla et al.
THERANOSTICS (2018)
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma
Jia Ruan et al.
BLOOD (2018)
Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
Chun-Yan Lan et al.
LANCET ONCOLOGY (2018)
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma A Nonrandomized Clinical Trial
Ajay K. Nooka et al.
JAMA ONCOLOGY (2018)
Pro-angiogenic peptides in biomedicine
Lucia De Rosa et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2018)
Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
Qing Zhang et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
Chloe Grasselly et al.
FRONTIERS IN IMMUNOLOGY (2018)
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study
Xin Yu et al.
CANCER COMMUNICATIONS (2018)
Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin
Xu Wang et al.
CLINICAL CANCER RESEARCH (2018)
Galectin-3 interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells
Florent Colomb et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
Jian Hou et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
Heather A. Wakelee et al.
LANCET ONCOLOGY (2017)
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L. Coleman et al.
LANCET ONCOLOGY (2017)
Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer
Benjamin S. Jones et al.
LUNG CANCER (2017)
A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer
Zhifei Zhao et al.
MEDICINE (2017)
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
Martina Schmittnaegel et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model
Manh-Cuong Vo et al.
ONCOTARGET (2017)
Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
Margaret E. Gatti-Mays et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes
Xinqi Wu et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
Alessandro Leonetti et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2017)
Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review
Ahmed M. Al-Abd et al.
JOURNAL OF ADVANCED RESEARCH (2017)
Adjuvant Chemotherapy for Stage II Colon Cancer: The Debate Goes On
James J. Lee et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
1052PDNIVOLUMAB (N) (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH SUNITINIB (S) OR PAZOPANIB (P) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
A. Amin et al.
ANNALS OF ONCOLOGY (2017)
Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
Michiru Nishita et al.
SCIENTIFIC REPORTS (2017)
First-line avelumab plus axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
A. Bamias et al.
ANNALS OF ONCOLOGY (2017)
Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas
Saori Okamoto et al.
BRAIN TUMOR PATHOLOGY (2016)
Lenvatinib: Role in thyroid cancer and other solid tumors
Maria E. Cabanillas et al.
CANCER TREATMENT REVIEWS (2016)
Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma
Keith A. Lawson et al.
CLINICAL CANCER RESEARCH (2016)
Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study
Alessio Giuseppe Morganti et al.
FUTURE ONCOLOGY (2016)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin et al.
NATURE COMMUNICATIONS (2016)
IL-17 Promotes Angiogenic Factors IL-6, IL-8, and Vegf Production via Stat1 in Lung Adenocarcinoma
Qi Huang et al.
SCIENTIFIC REPORTS (2016)
Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy
Helena Verdaguer et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
Awalpreet S. Chadha et al.
PLOS ONE (2016)
Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer
Igor M. Bondarenko et al.
BMC CANCER (2015)
Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer
V. Pernin et al.
BRITISH JOURNAL OF RADIOLOGY (2015)
Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma
Thanh-Nhan Nguyen-Pham et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Endostatin Combined with Platinum-Based Chemo-radiotherapy for Advanced Non-small Cell Lung Cancer
Xuan Jiang et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2015)
Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft
Gewen Tan et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer
H. Chen et al.
BRITISH JOURNAL OF CANCER (2014)
Recombinant human endostatin combined with radiotherapy in the treatment of brain metastases of non-small cell lung cancer
X. Jiang et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2014)
Extracellular regulation of VEGF: Isoforms, proteolysis, and vascular patterning
Prakash Vempati et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
Ramucirumab: First Global Approval
Raewyn M. Poole et al.
DRUGS (2014)
Endoplasmic Reticulum (ER) Stress and Hypoxia Response Pathways Interact to Potentiate Hypoxia-inducible Factor 1 (HIF-1) Transcriptional Activity on Targets Like Vascular Endothelial Growth Factor (VEGF)
Ethel R. Pereira et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
FOLFIRI-bevacizumab and concurrent low-dose radiotherapy in metastatic colorectal cancer: preliminary results of a phase I-II study
Alessio G. Morganti et al.
JOURNAL OF CHEMOTHERAPY (2014)
Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma
Hansen Bow et al.
JOURNAL OF NEUROSURGERY (2014)
Epidermal Growth Factor-like Domain 7 Predicts Response to First-Line Chemotherapy and Bevacizumab in Patients with Metastatic Colorectal Cancer
Torben Frostrup Hansen et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Third-line dovitinib in metastatic renal cell carcinoma
Manuela Schmidinger
LANCET ONCOLOGY (2014)
Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas
I. Sakamaki et al.
LEUKEMIA (2014)
Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer
Jing-Ping Yu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
The Role of Hypoxia Inducible Factor-1 in Hepatocellular Carcinoma
Dongjun Luo et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
Theerawut Chanmee et al.
CANCERS (2014)
Control of the immune response by pro-angiogenic factors
Thibault Voron et al.
FRONTIERS IN ONCOLOGY (2014)
Neuropilins: Role in Signalling, Angiogenesis and Disease
Ian Zachary
ANGIOGENESIS, LYMPHANGIOGENESIS AND CLINICAL IMPLICATIONS (2014)
Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo
S. Yasuda et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Angiopoietin signaling in the vasculature
Lauri Eklund et al.
EXPERIMENTAL CELL RESEARCH (2013)
HIFs, angiogenesis, and cancer
Yongzhi Yang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2013)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A Proangiogenic Signature Is Revealed in FGF-Mediated Bevacizumab-Resistant Head and Neck Squamous Cell Carcinoma
Rekha Gyanchandani et al.
MOLECULAR CANCER RESEARCH (2013)
Suppression of Antiviral Innate Immunity by Sunitinib Enhances Oncolytic Virotherapy
Babal K. Jha et al.
MOLECULAR THERAPY (2013)
Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart Disease Associated with Chemotherapy: A Meta-Analysis
Xing-Lin Chen et al.
PLOS ONE (2013)
Combining Antiangiogenic Therapy with Adoptive Cell Immunotherapy Exerts Better Antitumor Effects in Non-Small Cell Lung Cancer Models
Shujing Shi et al.
PLOS ONE (2013)
The Critical Impact of HIF-1a on Gastric Cancer Biology
Yoshihiko Kitajima et al.
Cancers (2013)
Predicting the Effects of Anti-angiogenic Agents Targeting Specific VEGF Isoforms
Stacey D. Finley et al.
AAPS JOURNAL (2012)
Contrasting effects of sunitinib within in vivo models of metastasis
Jonathan C. Welti et al.
ANGIOGENESIS (2012)
Prognostic Factors for Overall Survival in Patients With Metastatic Colorectal Carcinoma Treated With Vascular Endothelial Growth Factor-Targeting Agents
Bulent Cetin et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
P. Oliva et al.
BRITISH JOURNAL OF CANCER (2012)
Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway
Vesselina G. Cooke et al.
CANCER CELL (2012)
A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design
Edward B. Garon et al.
CLINICAL LUNG CANCER (2012)
VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
P. S. Sharma et al.
CURRENT CANCER DRUG TARGETS (2012)
Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice
Federica Maione et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors
Alicia S. Chung et al.
JOURNAL OF PATHOLOGY (2012)
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
Mallika Singh et al.
JOURNAL OF PATHOLOGY (2012)
Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small Cell Lung Cancer
Isamu Okamoto et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Combined vaccine plus axitinib therapy yields superior antitumor efficacy in a murine melanoma model
Anamika Bose et al.
MELANOMA RESEARCH (2012)
Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines
R. Grepin et al.
ONCOGENE (2012)
Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer - A two stage phase II clinical trial
Gudrun Resch et al.
RADIOTHERAPY AND ONCOLOGY (2012)
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
Zhong-Zhen Guan et al.
Chinese Journal of Cancer (2012)
Honokiol radiosensitizes colorectal cancer cells: enhanced activity in cells with mismatch repair defects
Zhiyun He et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2011)
Abstract 1401: Evaluation of vandetanib (ZD6474) and radiation therapy in an orthotopic xenograft model of anaplastic thyroid carcinoma
Yunyun Chen et al.
CANCER RESEARCH (2011)
Vandetanib First Global Approval
Helen Commander et al.
DRUGS (2011)
The role of pericytes in angiogenesis
Domenico Ribatti et al.
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2011)
Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
Bryan J. Schneider et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib
J. C. Welti et al.
ONCOGENE (2011)
Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study
Vaneja Velenik et al.
RADIATION ONCOLOGY (2011)
Angiogenesis
Donald R. Senger et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2011)
Bevacizumab (Avastin)
S. K. Mukherji
AMERICAN JOURNAL OF NEURORADIOLOGY (2010)
Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
V. Goede et al.
BRITISH JOURNAL OF CANCER (2010)
Angiogenesis Inhibitors: Current Strategies and Future Prospects
Kristina M. Cook et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
Rajeev K. Shrimali et al.
CANCER RESEARCH (2010)
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib
Camillo Porta et al.
KIDNEY INTERNATIONAL (2010)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Phase I/II Trial of Bevacizumab and Radiotherapy for Locally Advanced Inoperable Colorectal Cancer: Vasculature-Independent Radiosensitizing Effect of Bevacizumab
Michael I. Koukourakis et al.
CLINICAL CANCER RESEARCH (2009)
The Role of Macrophage-Derived IL-1 in Induction and Maintenance of Angiogenesis
Yaron Carmi et al.
JOURNAL OF IMMUNOLOGY (2009)
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
Annamaria Rapisarda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Systemic effects of local radiotherapy
Silvia C. Formenti et al.
LANCET ONCOLOGY (2009)
Biomarkers of response and resistance to antiangiogenic therapy
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Bevacizumab - A review of its use in metastatic colorectal cancer
Paul L. McCormack et al.
DRUGS (2008)
Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity
Jia Hu et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2008)
Cytokine regulation networks in the cancer microenvironment
Bor-Ching Sheu et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Lenalidomide in the treatment of multiple myeloma: a review
X. Armoiry et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2008)
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer:: an open-label randomised phase II study
Jean-Philippe Spano et al.
LANCET (2008)
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Jie Ma et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib
Jie Ma et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Hypoxic radiosensitization: Adored and ignored
Jens Overgaard
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bevacizumab in non-small cell lung cancer
Alan Sandler
CLINICAL CANCER RESEARCH (2007)
A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer
A. L. Thomas et al.
ANNALS OF ONCOLOGY (2007)
Endothelial cell migration during angiogenesis
Laurent Lamalice et al.
CIRCULATION RESEARCH (2007)
Interleukin-1β increases expression and activity of matrix metalloproteinase-2 in cardiac microvascular endothelial cells:: role of PKCα/β1 and MAPKs
Deidra J. H. Mountain et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2007)
Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay
Morikazu Amano et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors
J. A. Gietema et al.
ANNALS OF ONCOLOGY (2006)
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer
CH Crane et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Anti-tumor effect of radiation response by combined treatment with angiogenesis inhibitor, TNP-470, in oral squamous cell carcinoma
S Shintani et al.
ORAL ONCOLOGY (2006)
Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metal loproteinases
Y Tang et al.
CANCER RESEARCH (2005)
Matrix metalloproteinases and angiogenesis
JE Rundhaug
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2005)
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck
MM Cooney et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Inhibition of tumor angiogenesis during cisplatin chemotherapy for bladder cancer improves treatment outcome
CZ Kong et al.
UROLOGY (2005)
Imaging hypoxia and angiogenesis in tumors
JG Rajendran et al.
RADIOLOGIC CLINICS OF NORTH AMERICA (2005)
ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: Schedule-dependent enhancement of antitumor activity
KJ Williams et al.
CLINICAL CANCER RESEARCH (2004)
Cancer vaccines: Between the idea and the reality
OJ Finn
NATURE REVIEWS IMMUNOLOGY (2003)
Biology of angiogenesis in tumors of the gastrointestinal tract
N Reinmuth et al.
MICROSCOPY RESEARCH AND TECHNIQUE (2003)
Chemotherapy and antiangiogenesis - Drug-specific, dose-related effects
B Lennernas et al.
ACTA ONCOLOGICA (2003)
Role of VEGF family members and receptors in coronary vessel formation
RJ Tomanek et al.
DEVELOPMENTAL DYNAMICS (2002)
Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D
XR Li et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2001)
Share Paper
